Clinical Trial Update: An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy [Phase 1, Phase 2]

View source ↗

Summary

Open-label safety, tolerability, and dose-range finding study of nusinersen in spinal muscular atrophy completing phases 1 and 2 with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Nusinersen (nusinersen)

Snippet

Sponsor: Biogen | Conditions: Spinal Muscular Atrophy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-03-13